Form 4 for PLRX PLIANT THERAPEUTICS, INC.
Accepted 2024-07-11 00:00:00 ET · period of report 2024-07-09 · accession 0001746473-24-000113 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-07-11 | 2024-07-09 | PLRX | Coulie Bernard | Pres, CEO, Dir | A - Grant | $0.00 | +75.6K | 521.6K | +17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-09 | A | A | 75,625 | $0.00 | 521,646 | D | — | — | (F1) On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 75,625 shares. (F2) Includes 1,489 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program. |